Profile - To The Moon

MarcusLiong

Posts · 71Posts · 71
Following · 0Following · 0
Followers · 0Followers · 0

- MarcusLiongMarcusLiong
  ·2021-06-18
  Lalalalalalala
  2.90K Comment
  Like
  Share
  Report
- MarcusLiongMarcusLiong
  ·2021-06-18
  Come to me Mr T
  1.79K Comment
  Like
  Share
  Report
- MarcusLiongMarcusLiong
  ·2021-06-17
  Hello Kin give voucher
  2.27K Comment
  Like
  Share
  Report
- MarcusLiongMarcusLiong
  ·2021-06-17
  Show me the vouchers
  2.52K Comment
  Like
  Share
  Report
- MarcusLiongMarcusLiong
  ·2021-06-16
  Huat ahhhhhhhh
  2.46K Comment
  Like
  Share
  Report
- MarcusLiongMarcusLiong
  ·2021-06-16
  Hahaha
  Ocugen Secures Manufacturing Partnership for US Production of COVID-19 Vaccine Candidate, COVAXIN™
  Ocugen, Inc.(NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and comm
  Ocugen Secures Manufacturing Partnership for US Production of COVID-19 Vaccine Candidate, COVAXIN™
  2.66K Comment
  Like
  Share
  Report
- MarcusLiongMarcusLiong
  ·2021-06-15
  First to go last to come
  2.14K Comment
  Like
  Share
  Report
- MarcusLiongMarcusLiong
  ·2021-06-15
  Just la no
  2.27K Comment
  Like
  Share
  Report
- MarcusLiongMarcusLiong
  ·2021-06-15
  Wow.
  1.80K Comment
  Like
  Share
  Report
- MarcusLiongMarcusLiong
  ·2021-06-08
  Hi
  Sorry, this post has been deleted
  1.85K Comment
  3
  Share
  Report
No following yet

Most Discussed

{"i18n":{"language":"en_US"},"isCurrentUser":false,"userPageInfo":{"id":"3582475319067106","uuid":"3582475319067106","gmtCreate":1619381726116,"gmtModify":1620023045677,"name":"MarcusLiong","pinyin":"marcusliong","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.tigerbbs.com/eeba4d6764b4f4171e912d25e2484fc8","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":5,"headSize":57,"tweetSize":71,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":3,"name":"书生虎","nameTw":"書生虎","represent":"努力向上","factor":"发布10条非转发主帖,其中5条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-1","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Debut Tiger","description":"Join the tiger community for 500 days","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.10.30","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"7a9f168ff73447fe856ed6c938b61789-1","templateUuid":"7a9f168ff73447fe856ed6c938b61789","name":"Knowledgeable Investor","description":"Traded more than 10 stocks","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"972123088c9646f7b6091ae0662215be-2","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Master Trader","description":"Total number of securities or futures transactions reached 100","bigImgUrl":"https://static.tigerbbs.com/ad22cfbe2d05aa393b18e9226e4b0307","smallImgUrl":"https://static.tigerbbs.com/36702e6ff3ffe46acafee66cc85273ca","grayImgUrl":"https://static.tigerbbs.com/d52eb88fa385cf5abe2616ed63781765","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":"80.21%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":4,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":1,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":168777696,"gmtCreate":1623984876315,"gmtModify":1703825607738,"author":{"id":"3582475319067106","authorId":"3582475319067106","name":"MarcusLiong","avatar":"https://static.tigerbbs.com/eeba4d6764b4f4171e912d25e2484fc8","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582475319067106","idStr":"3582475319067106"},"themes":[],"htmlText":"Lalalalalalala","listText":"Lalalalalalala","text":"Lalalalalalala","images":[{"img":"https://static.tigerbbs.com/bb78aacec885f96c21e8278fd4c2f652","width":"1242","height":"2051"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/168777696","isVote":1,"tweetType":1,"viewCount":2898,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":168774996,"gmtCreate":1623984860415,"gmtModify":1703825605760,"author":{"id":"3582475319067106","authorId":"3582475319067106","name":"MarcusLiong","avatar":"https://static.tigerbbs.com/eeba4d6764b4f4171e912d25e2484fc8","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582475319067106","idStr":"3582475319067106"},"themes":[],"htmlText":"Come to me Mr T","listText":"Come to me Mr T","text":"Come to me Mr T","images":[{"img":"https://static.tigerbbs.com/cbf29974b311af85077955163d7a2633","width":"1242","height":"1906"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/168774996","isVote":1,"tweetType":1,"viewCount":1787,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":163374821,"gmtCreate":1623860906763,"gmtModify":1703821865141,"author":{"id":"3582475319067106","authorId":"3582475319067106","name":"MarcusLiong","avatar":"https://static.tigerbbs.com/eeba4d6764b4f4171e912d25e2484fc8","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582475319067106","idStr":"3582475319067106"},"themes":[],"htmlText":"Hello Kin give voucher","listText":"Hello Kin give voucher","text":"Hello Kin give voucher","images":[{"img":"https://static.tigerbbs.com/d12ab949ae266577128bde234026dd17","width":"1242","height":"1544"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/163374821","isVote":1,"tweetType":1,"viewCount":2274,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":163375437,"gmtCreate":1623860879729,"gmtModify":1703821864092,"author":{"id":"3582475319067106","authorId":"3582475319067106","name":"MarcusLiong","avatar":"https://static.tigerbbs.com/eeba4d6764b4f4171e912d25e2484fc8","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582475319067106","idStr":"3582475319067106"},"themes":[],"htmlText":"Show me the vouchers","listText":"Show me the vouchers","text":"Show me the vouchers","images":[{"img":"https://static.tigerbbs.com/d63a6cffe949fe77a1b2bcef5090f8ae","width":"1242","height":"1906"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/163375437","isVote":1,"tweetType":1,"viewCount":2520,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":160106086,"gmtCreate":1623773900545,"gmtModify":1703819121012,"author":{"id":"3582475319067106","authorId":"3582475319067106","name":"MarcusLiong","avatar":"https://static.tigerbbs.com/eeba4d6764b4f4171e912d25e2484fc8","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582475319067106","idStr":"3582475319067106"},"themes":[],"htmlText":"Huat ahhhhhhhh","listText":"Huat ahhhhhhhh","text":"Huat ahhhhhhhh","images":[{"img":"https://static.tigerbbs.com/40c144f271527eec4e1483fee19359c8","width":"1242","height":"2051"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/160106086","isVote":1,"tweetType":1,"viewCount":2461,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":160101089,"gmtCreate":1623773863441,"gmtModify":1703819117943,"author":{"id":"3582475319067106","authorId":"3582475319067106","name":"MarcusLiong","avatar":"https://static.tigerbbs.com/eeba4d6764b4f4171e912d25e2484fc8","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582475319067106","idStr":"3582475319067106"},"themes":[],"htmlText":"Hahaha","listText":"Hahaha","text":"Hahaha","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/160101089","repostId":"1178091722","repostType":4,"repost":{"id":"1178091722","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1623757022,"share":"https://ttm.financial/m/news/1178091722?lang=&edition=fundamental","pubTime":"2021-06-15 19:37","market":"us","language":"en","title":"Ocugen Secures Manufacturing Partnership for US Production of COVID-19 Vaccine Candidate, COVAXIN™","url":"https://stock-news.laohu8.com/highlight/detail?id=1178091722","media":"Tiger Newspress","summary":"Ocugen, Inc.(NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and comm","content":"<p></p>\n<p><img src=\"https://static.tigerbbs.com/30195a620eedea62e516df9d39d4d93b\" tg-width=\"663\" tg-height=\"440\">Ocugen, Inc.(NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, today announced that it has selected Jubilant HollisterStier of Spokane, Washington as its manufacturing partner forCOVAXIN™to prepare for potential commercial manufacturing of COVAXIN™ for the US and Canadian markets.</p>\n<p>“We are fully committed to bringing COVAXIN to the US and Canadian markets because we believe it has the potential to save lives by adding a weapon to the arsenal in the fight against emerging variants,” saidJ.P. Gabriel, Ocugen’s Senior Vice President, Manufacturing and Supply Chain. “Securing US-based manufacturing capability is a critical step as we prepare to submit our regulatory submissions to the FDA and Health Canada. Based on Bharat Biotech’s strong track record of developing and commercializing vaccines globally and Jubilant’s proven track record in manufacturing, we are well-prepared to transition US manufacturing of COVAXIN to our new partner.”</p>\n<p>“We are excited to expand our basket of vaccine products and meet the increasing demand from our customers for COVID-19 vaccines in the US,” said Amit Arora, President Jubilant HollisterStier.</p>\n<p>“We are pleased to partner with Ocugen and support the ongoing fight against COVID-19. With two facilities in North America working to manufacture multiple COVID-19 vaccines and therapies, we remain committed to supporting efforts to eradicate this global pandemic,” stated Pramod Yadav, CEO Jubilant Pharma Limited.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ocugen Secures Manufacturing Partnership for US Production of COVID-19 Vaccine Candidate, COVAXIN™</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOcugen Secures Manufacturing Partnership for US Production of COVID-19 Vaccine Candidate, COVAXIN™\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-06-15 19:37</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p></p>\n<p><img src=\"https://static.tigerbbs.com/30195a620eedea62e516df9d39d4d93b\" tg-width=\"663\" tg-height=\"440\">Ocugen, Inc.(NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, today announced that it has selected Jubilant HollisterStier of Spokane, Washington as its manufacturing partner forCOVAXIN™to prepare for potential commercial manufacturing of COVAXIN™ for the US and Canadian markets.</p>\n<p>“We are fully committed to bringing COVAXIN to the US and Canadian markets because we believe it has the potential to save lives by adding a weapon to the arsenal in the fight against emerging variants,” saidJ.P. Gabriel, Ocugen’s Senior Vice President, Manufacturing and Supply Chain. “Securing US-based manufacturing capability is a critical step as we prepare to submit our regulatory submissions to the FDA and Health Canada. Based on Bharat Biotech’s strong track record of developing and commercializing vaccines globally and Jubilant’s proven track record in manufacturing, we are well-prepared to transition US manufacturing of COVAXIN to our new partner.”</p>\n<p>“We are excited to expand our basket of vaccine products and meet the increasing demand from our customers for COVID-19 vaccines in the US,” said Amit Arora, President Jubilant HollisterStier.</p>\n<p>“We are pleased to partner with Ocugen and support the ongoing fight against COVID-19. With two facilities in North America working to manufacture multiple COVID-19 vaccines and therapies, we remain committed to supporting efforts to eradicate this global pandemic,” stated Pramod Yadav, CEO Jubilant Pharma Limited.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"OCGN":"Ocugen"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1178091722","content_text":"Ocugen, Inc.(NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, today announced that it has selected Jubilant HollisterStier of Spokane, Washington as its manufacturing partner forCOVAXIN™to prepare for potential commercial manufacturing of COVAXIN™ for the US and Canadian markets.\n“We are fully committed to bringing COVAXIN to the US and Canadian markets because we believe it has the potential to save lives by adding a weapon to the arsenal in the fight against emerging variants,” saidJ.P. Gabriel, Ocugen’s Senior Vice President, Manufacturing and Supply Chain. “Securing US-based manufacturing capability is a critical step as we prepare to submit our regulatory submissions to the FDA and Health Canada. Based on Bharat Biotech’s strong track record of developing and commercializing vaccines globally and Jubilant’s proven track record in manufacturing, we are well-prepared to transition US manufacturing of COVAXIN to our new partner.”\n“We are excited to expand our basket of vaccine products and meet the increasing demand from our customers for COVID-19 vaccines in the US,” said Amit Arora, President Jubilant HollisterStier.\n“We are pleased to partner with Ocugen and support the ongoing fight against COVID-19. With two facilities in North America working to manufacture multiple COVID-19 vaccines and therapies, we remain committed to supporting efforts to eradicate this global pandemic,” stated Pramod Yadav, CEO Jubilant Pharma Limited.","news_type":1,"symbols_score_info":{"OCGN":0.9}},"isVote":1,"tweetType":1,"viewCount":2661,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":187847337,"gmtCreate":1623750386329,"gmtModify":1704210429033,"author":{"id":"3582475319067106","authorId":"3582475319067106","name":"MarcusLiong","avatar":"https://static.tigerbbs.com/eeba4d6764b4f4171e912d25e2484fc8","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582475319067106","idStr":"3582475319067106"},"themes":[],"htmlText":"First to go last to come&nbsp;","listText":"First to go last to come&nbsp;","text":"First to go last to come","images":[{"img":"https://static.tigerbbs.com/b023646799d63ee3f92edfc45559fcfc","width":"1242","height":"1544"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/187847337","isVote":1,"tweetType":1,"viewCount":2143,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":187845400,"gmtCreate":1623750350000,"gmtModify":1704210427085,"author":{"id":"3582475319067106","authorId":"3582475319067106","name":"MarcusLiong","avatar":"https://static.tigerbbs.com/eeba4d6764b4f4171e912d25e2484fc8","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582475319067106","idStr":"3582475319067106"},"themes":[],"htmlText":"Just la no&nbsp;","listText":"Just la no&nbsp;","text":"Just la no","images":[{"img":"https://static.tigerbbs.com/6116b76b7acfe4e02c4a2db4f4806c1f","width":"1242","height":"1544"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/187845400","isVote":1,"tweetType":1,"viewCount":2274,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":187821034,"gmtCreate":1623749705328,"gmtModify":1704210392343,"author":{"id":"3582475319067106","authorId":"3582475319067106","name":"MarcusLiong","avatar":"https://static.tigerbbs.com/eeba4d6764b4f4171e912d25e2484fc8","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582475319067106","idStr":"3582475319067106"},"themes":[],"htmlText":"Wow. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;","listText":"Wow. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;","text":"Wow.","images":[{"img":"https://static.tigerbbs.com/6116b76b7acfe4e02c4a2db4f4806c1f","width":"1242","height":"1544"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/187821034","isVote":1,"tweetType":1,"viewCount":1804,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":117274634,"gmtCreate":1623147294528,"gmtModify":1704197044364,"author":{"id":"3582475319067106","authorId":"3582475319067106","name":"MarcusLiong","avatar":"https://static.tigerbbs.com/eeba4d6764b4f4171e912d25e2484fc8","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582475319067106","idStr":"3582475319067106"},"themes":[],"htmlText":"Hi","listText":"Hi","text":"Hi","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/117274634","repostId":"1136550999","repostType":4,"isVote":1,"tweetType":1,"viewCount":1854,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"defaultTab":"following","isTTM":true}